Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351231 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03351231 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7 participants.
The verdict
NCT03351231, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
Interventions
- BIOLOGICAL Nivolumab
- DRUG BMS-986242
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2018-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03351231
The ClinicalTrials.gov registry entry for NCT03351231 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03351231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03351231 about?
NCT03351231 is a clinical study titled "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer". The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
What is the current status of trial NCT03351231?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-11-27. Estimated completion is 2018-08-28.
What interventions are being tested in trial NCT03351231?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BMS-986242 (DRUG).
Who is sponsoring clinical trial NCT03351231?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.